Lucy Kilburn

7.2k total citations · 2 hit papers
64 papers, 2.1k citations indexed

About

Lucy Kilburn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Lucy Kilburn has authored 64 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 30 papers in Cancer Research. Recurrent topics in Lucy Kilburn's work include Breast Cancer Treatment Studies (23 papers), Estrogen and related hormone effects (21 papers) and Advanced Breast Cancer Therapies (17 papers). Lucy Kilburn is often cited by papers focused on Breast Cancer Treatment Studies (23 papers), Estrogen and related hormone effects (21 papers) and Advanced Breast Cancer Therapies (17 papers). Lucy Kilburn collaborates with scholars based in United Kingdom, United States and Netherlands. Lucy Kilburn's co-authors include Judith M. Bliss, R. Charles Coombes, Mitch Dowsett, Nicholas C. Turner, Charlotte Fribbens, Matthew Beaney, Isaac García-Murillas, Sarah Hrebien, Claire Snowdon and Ben O’Leary and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Lucy Kilburn

58 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

2016 507 citations Charlotte Fribbens, Lucy Kilburn et al. profile →
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

2011 449 citations Tom Treasure, Loı̈c Lang-Lazdunski et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Lucy Kilburn

Since Specialization

Citations

This map shows the geographic impact of Lucy Kilburn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucy Kilburn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucy Kilburn more than expected).

Fields of papers citing papers by Lucy Kilburn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucy Kilburn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucy Kilburn. The network helps show where Lucy Kilburn may publish in the future.

Co-authorship network of co-authors of Lucy Kilburn

This figure shows the co-authorship network connecting the top 25 collaborators of Lucy Kilburn. A scholar is included among the top collaborators of Lucy Kilburn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucy Kilburn. Lucy Kilburn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial 2025 ·Radiotherapy and Oncology ·(unknown), Lucy Kilburn, Anna M. Kirby, Clare Griffin, Mark Sydenham, Cliona Kirwan, Joanne Haviland, Indrani Bhattacharya, Monica Jefford, Isabel Syndikus, Judith M. Bliss, Charlotte E. Coles	1
2	Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials 2025 ·Radiotherapy and Oncology ·(unknown), Anna M. Kirby, Lucy Kilburn, Clare Griffin, Mark Sydenham, (unknown), Cliona Kirwan, Monica Jefford, Isabel Syndikus, Judith M. Bliss, Charlotte E. Coles	0
3	Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies 2024 ·npj Breast Cancer ·(unknown), Mothaffar F. Rimawi, Stephen Johnston, Samuel A. Jacobs, Judith M. Bliss, Katherine L. Pogue–Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, (unknown), Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu	0
4	ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 -Mutant Breast Cancer 2023 ·Cancer Discovery ·Belinda Kingston, Alex Pearson, María Teresa Herrera-Abreu, (unknown), Rosalind Cutts, (unknown), Laura Moretti, Lucy Kilburn, (unknown), Iain R. Macpherson, Alistair Ring, Judith M. Bliss, (unknown), Weiyi Toy, John A. Katzenellenbogen, Sarat Chandarlapaty, Nicholas C. Turner	21
5	Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) 2023 ·Clinical Cancer Research ·Holly Tovey, (unknown), Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazińska, Sarah E. Pinder, Judith M. Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie C.U. Cheang	3
6	Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study 2022 ·Breast Cancer Research ·Elena López‐Knowles, Simone Detre, Margaret Hills, Eugene F. Schuster, Maggie C.U. Cheang, Holly Tovey, Lucy Kilburn, Judith M. Bliss, J.F.R. Robertson, Elizabeth Mallon, Anthony Skene, Abigail Evans, Ian Smith, Mitch Dowsett	5
7	HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours 2021 ·Lung Cancer ·Fiona McDonald, Matthias Gückenberger, Sanjay Popat, Corinne Faivre‐Finn, Nicolaus Andratschke, Angela M. Riddell, Gerard G. Hanna, Vineet Prakash, Arjun Nair, Patricia Díez, Priyanka Patel, Lucy Kilburn, Christy Toms, Judith M. Bliss	0
8	ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials 2020 ·Clinical Cancer Research ·Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac García-Murillas, Aman U. Budzar, J.F.R. Robertson, William J. Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen Johnston, Stephen Chia	100
9	Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial 2020 ·The Lancet Oncology ·Ian Smith, J.F.R. Robertson, Lucy Kilburn, Maggie Wilcox, Abigail Evans, Chris Holcombe, Kieran Horgan, Cliona Kirwan, Elizabeth Mallon, Mark Sibbering, Anthony Skene, Raghavan Vidya, Maggie C.U. Cheang, Jane Banerji, James P. Morden, Kally Sidhu, Andrew Dodson, Judith M. Bliss, Mitch Dowsett	147
10	TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001) 2017 ·European Thyroid Journal ·Ilaria Muller, Lucy Kilburn, Peter Taylor, Peter Barrett‐Lee, Judith M. Bliss, Peter Ellis, Marian Ludgate, Colin Dayan	17
11	Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository 2017 ·Trials ·Lucy Kilburn, Maria Aresu, Jane Banerji, Peter Barrett‐Lee, Peter Ellis, Judith M. Bliss	7
12	Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) 2016 ·Annals of Oncology ·Christy Toms, Neha Chopra, (unknown), (unknown), Lucy Kilburn, Judith M. Bliss, Nicholas C. Turner	8
13	Epirubicin dose and sequential hormonal therapy—Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer 2016 ·European Journal of Cancer ·R. Charles Coombes, Lucy Kilburn, N. Tubiana-Mathieu, (unknown), Aart van Bochove, Faustino R. Pérez‐López, Carlo Palmieri, Justin Stebbing, Judith M. Bliss	5
14	Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052) 2016 ·Annals of Oncology ·Susana Banerjee, Lucy Kilburn, Rebecca Bowen, Holly Tovey, Marcia Hall, Stan B. Kaye, Gordon Rustin, Martin Gore, Jennifer McLachlan, Ayoma D. Attygalle, Nina Tunariu, João Paulo da Silveira Nogueira Lima, Peter Chatfield, (unknown), Elizabeth Folkerd, Margaret Hills, Sophie Perry, Gerhardt Attard, Mitch Dowsett, Judith M. Bliss	2
15	Treatment of the axilla in patients with primary breast cancer and low burden axillary disease: Limitations of the evidence from randomised controlled trials 2016 ·Critical Reviews in Oncology/Hematology ·J.F.R. Robertson, P Herrod, (unknown), Lucy Kilburn, Charlotte E. Coles, Ian Bradbury	9
16	The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective 2014 ·Trials ·Lucy Kilburn, Jane Banerji, Judith M. Bliss	8
17	The MARS feasibility trial: conclusions not supported by data reply 2011 ·Pure Amsterdam UMC ·Judith M. Bliss, Gill Coombes, Liz Darlison, John Edwards, James Entwisle, Lucy Kilburn, David Landau, Loı̈c Lang-Lazdunski, Mary Claire O’Brien, Kenneth J. O’Byrne, Julian Peto, Suresh Senan, M. Snee, James Spicer, Carol Tan, Gill Thomas, Tom Treasure, David Waller	4
18	Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase? 2011 ·British Journal of Cancer ·Robert Leonard, Rachel Ballinger, David Cameron, Peter Ellis, Lesley Fallowfield, Margot Gosney, L. Johnson, Lucy Kilburn, Andreas Makris, J Mansi, Malcolm Reed, Alistair Ring, A. Robinson, Peter Simmonds, Gerry Thomas, Judith M. Bliss	33
19	Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study breakdown → 2011 ·The Lancet Oncology ·Tom Treasure, Loı̈c Lang-Lazdunski, David Waller, Judith M. Bliss, Carol Tan, James Entwisle, M. Snee, Mary Claire O’Brien, Gill Thomas, Suresh Senan, Kenneth J. O’Byrne, Lucy Kilburn, James Spicer, David Landau, John Edwards, Gill Coombes, Liz Darlison, Julian Peto	449
20	Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study 2007 ·The Lancet Oncology ·Robert E. Coleman, Linda M. Banks, Samia I. Girgis, Lucy Kilburn, Eduard Vrdoljak, John Fox, Simon Cawthorn, Ashraf Patel, Claire Snowdon, Emma Hall, Judith M. Bliss, R. Charles Coombes	321

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact